Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

This was the stock's second consecutive day of losses.

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

CRISPR stock skyrocketed to $199 in 2021, but has since fallen 74% to its current price of $50. This gives the firm a $4.3bn ...

Lockheed Martin ( NYSE: LMT) and Rolls Royce (LON: RR) Allen views this as one of the megatrends of the next five years, with ...

Bayko covers the Healthcare sector, focusing on stocks such as Insmed, Alnylam Pharma, and Vertex Pharmaceuticals ... H.C. Wainwright also maintained a Buy rating on the stock with a $11.50 price ...